„D-dimerosis” among the patients with the cancer it is always needed to be treated? Review article
Article Sidebar
Main Article Content
Abstract
The risk of thromboembolic disease increases in malignant tumors. D-dimer is a product of fibrin degradation. Its concentration rises in neoplasms, but also in another diseases characterized by activation of clotting and fibrinolysis, and therefore has low specificity. Elevated level of D-dimer gives a low positive predictive value to confirm thromboembolic disease and should not be used to confirm it. However its high negative predictive value allows reliable exclusion of thromboembolic disease provided pretest clinical probability is taken into account. In clinical practice D-dimer has to be measured by a sensitive tests, and the immunoenzymatic tests (VIDAS) seem to be the best in oncology. D-dimers can be useful to assess the risk of thromboembolic event recurrence after stopping anticoagulation. Additionally it can be used for the diagnosis of disseminant intravascular coagulation and as a marker of malignant tumor progression or reccurence.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Torbicki A., Perrier A., Konstatinides S. et al.: Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur. Heart J. 2008; 29(18): 2276-315.
3. Le G., Righini M., Roy P. et al.: Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann. Intern. Med. 2006; 144(3): 165-171.
4. Miron M., Perrier A., Bounameaux H. et al.: Contribution of noninvasive evaluation to the diagnosis of pulmonary embolism in hospitalized patients. Eur. Respir. J. 1999; 13(6): 1365-1370.
5. Raimondi P., Bongard O., de Moerloose P. et al.: D-dimer plasma concentration in various clinical conditions: implication for use of this test in the diagnostic approach of venous thromboembolism. Thromb. Res. 1993; 69: 125-130.
6. Kearon C., Kahn S., Agnelli G.: Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 Jun; 133(6 Suppl): 454S-545S.
7. Carrier M., Lee A., Bates S. et al.: Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. Thromb. Res. 2008; 123(1): 177-83.
8. Sohne M., Kruip M., Nijkeuter M. et al.: Acuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous thromboembolism, COPD or heart failure and in older patients wit suspected pulmonary embolism. J. Thromb. Haemost. 2006; 4: 1042-1046.
9. Young S., Robinson B.: Venous thromboembolism in cancer patients in Christchurch. NZ Med. J. 2002; 115(1155): 257-60.
10. Lee A., Rickles F., Julian J. et al.: Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J. Clin. Oncol. 2005; 23(10): 2123-9.
11. Palareti G., Cosmi B., Legnani C. et al.: D-dimer testing to determine the duration of anticoagulation therapy. N. Engl. J. Med. 2006; 355: 1780-1789.
12. Sallach S., Wan J., Nguyen N. et al.: Diseeminated intravascular coagulation in solid tumors:clinical and pathologic study. Thromb. Haemost. 2001; 86(3): 828-33.
13. Knowlson L., Bacchu S., Paneesha S. et al.: Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism. J. Clin. Pathol. 2010 Sep; 63(9): 818-22.
14. Nagy Z., Horváth O. et al.: D-Dimer as a Potential Prognostic Marker. Pathol. Oncol. Res. 2012 Jan 28.
15. Oya M., Akiyama Y., Yanagida T.: Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg. Today 1998; 28(4): 373-8.
16. Buccheri G., Torchio P., Ferrigno D.: Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003; 97(12): 3044-52.
17. Dirix L.Y., Salgado R., Weytjens R. et al.: Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br. J. Cancer 2002 Feb 1; 86(3): 389-95.